Immunic is a late-stage biotechnology company developing oral, small-molecule therapies for neurologic and gastrointestinal diseases, with headquarters in New York and principal operations in Germany. The company's lead candidate, vidofludimus calcium, is in Phase 3 development for relapsing multiple sclerosis and Phase 2 development for progressive MS, employing dual mechanisms of selective immune cell inhibition and neuroprotection, while a second program targets intestinal barrier function restoration for celiac disease and inflammatory bowel disease. Immunic has no commercial revenue and depends on successful clinical development, regulatory approvals, and subsequent commercialization for future profitability, having funded operations historically through equity offerings and strategic financing.